Summarized by Masters of Longevity from Science Daily - Health & Medicine.
Stopping treatment with GLP‑1 drugs: a health news article that examines cardiovascular risks linked to discontinuing these widely used diabetes and weight‑loss medications, offering context and implications for patients and clinicians.
Key Takeaways
- A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops.
- After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.
- Stopping Ozempic may raise heart attack and stroke risk.
